Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
Sarah J. Morgan, … , Pradeep K. Singh, the PROMISE-Micro Study Group
Sarah J. Morgan, … , Pradeep K. Singh, the PROMISE-Micro Study Group
Published September 5, 2024
Citation Information: J Clin Invest. 2024;134(20):e184171. https://doi.org/10.1172/JCI184171.
View: Text | PDF
Research Letter Microbiology

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Abstract

Authors

Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group

×

Supporting data values - Download (63.12 KB)

No preview available for this file type: xlsx
Use the download link to access the file.
Advertisement